|1.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
|5.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|1.||Taheri, Saeed: 28 articles (11/2014 - 01/2007)|
|2.||Khedmat, Hossein: 21 articles (03/2015 - 07/2009)|
|3.||Gaidano, Gianluca: 18 articles (06/2015 - 11/2003)|
|4.||Morra, Enrica: 16 articles (03/2013 - 01/2002)|
|5.||Capello, Daniela: 14 articles (03/2013 - 11/2003)|
|6.||Rossi, Davide: 13 articles (03/2015 - 11/2003)|
|7.||Paulli, Marco: 13 articles (11/2013 - 11/2003)|
|8.||Tsai, Donald E: 12 articles (06/2013 - 11/2002)|
|9.||Dierickx, Daan: 11 articles (11/2015 - 07/2009)|
|10.||Bhagat, Govind: 11 articles (11/2015 - 01/2004)|
|1.||rituximab (Mabthera)FDA Link
03/01/2009 - "Despite very limited in number, these results suggest that rituximab is very effective in the treatment of PRCA complicating B-cell chronic lymphoproliferative disorders."
01/01/2010 - "Rituximab use in hematology and oncology practice has significantly and positively improved the clinical outcomes in patients with a wide variety of B-cell lymphoproliferative disorders. "
10/01/2010 - "Incorporation of rituximab into the therapeutic armamentarium of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder has clearly improved the overall prognosis of this dreadful disease. "
08/01/2013 - "The anti-CD20 antibody rituximab depletes B cells, leading to improved outcomes for patients with EBV-associated B-lymphoproliferative disorders. "
05/01/2009 - "Our studies reveal the proteomic consequences of rituximab treatment and provide novel insights into the mechanism of action of the drug in susceptible B-cell lymphoproliferative disorders."
|2.||Methotrexate (Mexate)FDA LinkGeneric
04/01/1998 - "In conclusion, the rate of occurrence of lymphoproliferative disorders induced by low-dose methotrexate therapy remains controversial, although the characteristics of the malignancies and the possibility of a complete remission after methotrexate withdrawal militate against a chance association. "
07/01/2011 - "FDG PET/CT in a patient with spontaneous remission of methotrexate-associated lymphoproliferative disorders after interruption of methotrexate."
01/01/2015 - "However, several studies have shown that methotrexate has been associated with the development of lymphoproliferative disorders, namely methotrexate-associated lymphoproliferative disorders. "
07/01/2014 - "Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases."
01/01/2006 - "Immunohistochemical study demonstrated that immunoblasts usually were CD20+, and a portion of them was CD30+. The histomorphological findings of the present case are similar to those of methotrexate (MTX)-induced atypical lymphoproliferative disorders (LPDs) in some aspects. "
12/01/2002 - "We discuss the possible therapeutic implications of this finding and establish a comparison between immunophenotype and sensitivity to purine analogues in patients with T-PLL and other chronic lymphoproliferative disorders."
06/01/2001 - "The purine nucleoside analogues, either alone or in combination with other chemotherapeutic agents, are increasingly used in the treatment of patients with indolent B-cell lymphoproliferative disorders. "
10/01/1995 - "Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders."
01/01/1993 - "Purine analogs in lymphoproliferative disorders."
11/01/1991 - "CdA is a purine analogue with useful clinical activity against lymphoproliferative disorders and it has recently been found to be the single most active agent in the treatment of hairy cell leukaemia. "
|4.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/01/2005 - "The combination of FDR and cyclophosphamide (Cy) has been shown to be effective in chronic lymphoproliferative disorders. "
08/01/2014 - "Most patients received ASCT, but 106 patients who received high-dose cyclophosphamide without ASCT were also included in this study, as this is our institutional standard for malignant and nonmalignant lymphoproliferative disorders in need of HDT. "
10/01/2013 - "Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis."
08/01/1986 - "Cyclophosphamide is a well established cytotoxic drug used in the treatment of lymphoproliferative disorders, certain solid tumors, and nonneoplastic disorders such as nephrotic syndrome, systemic lupus erythematosus and rheumatoid arthritis. "
11/01/1983 - "Cyclophosphamide is a well established cytotoxic drug used in the treatment of lymphoproliferative disorders, certain solid tumors, and nonneoplastic disorders such as the nephrotic syndrome, systemic lupus erythematosus, and rheumatoid arthritis. "
|5.||Etoposide (VP 16)FDA LinkGeneric
05/01/2008 - "Etoposide shows both in vitro and in vivo efficacy for Epstein-Barr virus-associated lymphoproliferative disorders. "
01/01/1997 - "Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy."
12/01/2003 - "Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide."
07/01/2001 - "Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV)."
12/01/2003 - "This pilot study assessed the feasibility and efficacy of salvage chemotherapy (carboplatin and etoposide; CE) supported by granulocyte colony-stimulating factor (GCSF) in patients with refractory or relapsed post-transplant lymphoproliferative disorder (PTLD) following solid organ transplantation. "
06/01/2012 - "Comprehensive information on the subcellular distributions and responses of p53, p63 and p73 to 2-FaraA provides additional insight into mechanisms for induction of apoptosis in the treatment of B-lymphoproliferative disorders with fludarabine."
12/01/2010 - "These Epstein-Barr virus-B-cell lymphoproliferative disorders are thought to be related to immune suppression induced by fludarabine/other chemotherapeutic regimens. "
02/01/2009 - "Fludarabine exposure leads to impaired peripheral blood stem cell (PBSC) mobilization in indolent lymphoproliferative disorders (LPD). "
07/01/2003 - "The patient was managed as an indo-lent/low-grade lymphoproliferative disorder with excellent response to eight cycles of fludarabine."
06/01/1998 - "These cases confirm the high incidence of AIHA after FAMP and suggest that the use of highly effective lymphocytotoxic agents such as fludarabine in heavily pretreated patients increases the risk of AIHA in CLL and other lymphoproliferative disorders."
01/02/2012 - "Monoclonal antibodies surface expression using lymphoproliferative disorders panel (CD45, CD19, CD5, CD10, CD11c, CD20, CD22, CD23, CD38, CD79b, FMC7, CD103, CD25, kappa and lambda light chains) by flow cytometry was done on bone marrow samples. "
09/01/2008 - "Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is associated with the use of increasingly larger panels of multiple combinations of 3 to > or =6 monoclonal antibodies (Mab), data analysis being separately performed for each of the different stained sample aliquots. "
10/01/2006 - "To describe the value of monoclonal antibodies in the differential diagnosis of orbital lymphoproliferative disorders. "
03/01/2002 - "Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed."
03/01/2002 - "Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. "
01/01/2000 - "Cladribine (2-chlorodeoxyadenosine, 2-CDA) is effective in the treatment of various lymphoproliferative disorders. "
07/01/1995 - "2-Chloro-2'-deoxyadenosine (CdA), a newly developed anticancer drug, has been tested in phase II trials in the treatment of lymphoproliferative disorders. "
10/21/2010 - "However, cladribine's impressive activity in other lymphoproliferative disorders has been generally underappreciated. "
08/10/2007 - "[Remarkable response to cladribine in the treatment for hairy B cell lymphoproliferative disorder]."
06/01/1997 - "The efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in cutaneous T-cell lymphoproliferative disorders was examined. "
|9.||alemtuzumab (Campath)FDA Link
10/01/2003 - "Alemtuzumab appears to be an effective and well-tolerated therapy for pure red blood cell aplasia associated with lymphoproliferative disorders."
08/15/2003 - "The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders. "
08/15/2003 - "Phase II study of alemtuzumab in chronic lymphoproliferative disorders."
01/01/2001 - "More clinical trials in a larger number of patients are necessary to determine the exact role and indications of Campath-1H in lymphoproliferative disorders."
10/01/2008 - "Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder."
|10.||Sirolimus (Rapamycin)FDA Link
05/01/2006 - "Sirolimus-induced remission of posttransplantation lymphoproliferative disorder."
06/01/2008 - "Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders."
12/01/2012 - "We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus."
06/01/2011 - "Long-term maintenance therapy for post-cardiac transplant monoclonal lymphoproliferative disorder: caveat mammalian target of rapamycin."
08/01/2003 - "Here we demonstrate that the immunosuppressant rapamycin (RAPA) has a strong antiproliferative effect in vitro on B-cell lines derived from organ transplant recipients with EBV-associated posttransplant lymphoproliferative disorder (PTLD). "
11/26/2009 - "Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) to solid organ transplant (SOT) recipients has been shown safe and effective for the treatment of EBV-associated posttransplantation lymphoproliferative disorders (PTLDs). "
03/01/2014 - "Remission was achieved, and follow-up at 76 months after transplant showed no recurrence of the posttransplant lymphoproliferative disorder. "
04/01/2011 - "Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants."
01/01/2002 - "Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment."
10/27/1999 - "After the diagnosis of posttransplant lymphoproliferative disorder, immunosuppression was reduced with a subsequent partial improvement in the endoscopic appearance of the graft and a focal decrease in the lymphocytic infiltrate seen in the follow-up biopsies. "
|2.||Transplantation (Transplant Recipients)
04/15/2006 - "B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication of transplantation, with no consensus on best treatment practice. "
08/01/2013 - "We report a case of PCNS lymphoproliferative disorder in a kidney transplant recipient, which underwent complete remission with decreasing immunosuppression. "
01/01/2006 - "Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery."
07/01/2006 - "Encouraging evidence is accumulating for the efficacy of reduced intensity transplantation in indolent lymphoproliferative disorders. "
10/01/2002 - "Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease."
|3.||Drug Therapy (Chemotherapy)
05/01/2012 - "Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany."
03/01/2012 - "Efficient chemotherapy, tailored to the underlying plasma cell or lymphoproliferative disorder and adapted to renal function, should be promptly introduced, even in the absence of overt malignant haematological disease. "
10/01/2011 - "Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients."
12/27/2007 - "Currently no standard treatment exists for patients with posttransplant lymphoproliferative disorders relapsed or refractory to chemotherapy after failure of reduction in immunosuppression. "
07/01/2006 - "Indolent lymphoproliferative disorders are incurable with conventional chemotherapy. "
12/01/2014 - "Previous studies of donor or recipient origin of posttransplant lymphoproliferative disorders (PTLDs) following solid organ transplantation (SOT) have either been small or with selected patient groups. "
07/01/1994 - "To study the histopathologic findings, clinical course, and therapeutic outcome of patients who developed a lymphoproliferative disorder after undergoing solid organ transplantation. "
10/01/2015 - "Posttransplant lymphoproliferative disorder (PTLD) is a heterogeneous group of clinical and pathological entities characterized by malignant lymphoid cell proliferation occurring after solid organ transplantation, with frequent extranodal involvement. "
09/01/2015 - "Posttransplant lymphoproliferative disorder (PTLD) is a known complication of solid organ transplantation. "
07/01/2015 - "Posttransplant lymphoproliferative disorder (PTLD) is a known complication of organ transplantation, but musculoskeletal involvement of PTLD remains very rare. "
11/01/1998 - "Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy."
01/01/2011 - "We analyzed data from 27 studies that included 303 patients with lymphoproliferative disorders after renal transplantation. "
11/01/1981 - "Clinical, pathological, serological, and molecular hybridization studies provide substantial evidence that EBV was the cause of these lymphoproliferative disorders occurring after renal transplantation. "
04/01/2015 - "[A case of lymphoproliferative disorder in the entire small intestine after renal transplantation detected by wireless capsule endoscopy]."
07/01/2013 - "Spectrum of lymphoproliferative disorders following renal transplantation in North India."